With this platform and UHPLC-LTQ-Orbitrap MS, Western blotting, and immunofluorescence, we eventually determined the chemical composition of XZR and its possible mechanism of action in the treatment of migraine, and we preliminarily confirmed the active components in XZR with the NOS inhibitory activity. The gene discussed is NOS2; the disease is migraine disorder.